Valuation: Viridian Therapeutics, Inc.

Market Cap 2.53B 2.26B 2.09B 1.89B 3.54B 241B 3.6B 25.16B 9.96B 126B 9.51B 9.31B 397B P/E 2026 *
-5.64x
P/E 2027 * -8.73x
Enterprise Value 1.75B 1.56B 1.44B 1.31B 2.44B 166B 2.48B 17.35B 6.87B 86.9B 6.56B 6.42B 274B EV / Sales 2026 *
71.7x
EV / Sales 2027 * 8.7x
Free-Float
99.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Viridian Therapeutics, Inc.

1 day-1.97%
1 week+17.55%
Current month+8.64%
1 month+4.39%
3 months+16.15%
6 months+57.20%
Current year-28.12%
1 week 19.07
Extreme 19.07
23.59
1 month 17.59
Extreme 17.59
23.59
Current year 13.18
Extreme 13.18
34.29
1 year 13.18
Extreme 13.18
34.29
3 years 9.9
Extreme 9.9
34.29
5 years 9.47
Extreme 9.47
39
10 years 4.67
Extreme 4.665004
270
Manager TitleAgeSince
Chief Executive Officer 55 2023-10-29
Director of Finance/CFO 46 2023-09-11
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Director/Board Member 74 2018-01-02
Chairman 40 2021-05-31
Director/Board Member 51 2021-07-13
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Sell

General Counsel

-34,212 0.0358%
8/14/26 Exercice

Chief Technology Officer

80,000 0.0838%
7/1/26 Free

Director

32,341 0.0339%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%+17.55%+1.36%+101.17% 2.53B
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.05%+3.84%+44.69%+151.91% 38.56B
Weighted average by Cap. +0.37%+2.82%+47.27%+158.20%

Financials

2026 *2027 *
Net sales 24.38M 21.77M 20.11M 18.23M 34.1M 2.31B 34.67M 242M 95.83M 1.21B 91.5M 89.56M 3.82B 234M 209M 193M 175M 327M 22.18B 332M 2.32B 918M 11.62B 877M 858M 36.63B
Net income -466M -416M -384M -348M -651M -44.19B -662M -4.62B -1.83B -23.15B -1.75B -1.71B -73B -320M -286M -264M -239M -448M -30.38B -455M -3.18B -1.26B -15.92B -1.2B -1.18B -50.18B
Net Debt -787M -703M -649M -588M -1.1B -74.72B -1.12B -7.81B -3.09B -39.15B -2.95B -2.89B -123B -501M -448M -413M -375M -701M -47.58B -713M -4.98B -1.97B -24.93B -1.88B -1.84B -78.6B
Projected Income Statement - Annual - Viridian Therapeutics, Inc.
Logo Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Employees
252
Date Price Change Volume
26-10-23 US$22.37 -1.97% 1,179,022
26-10-22 US$22.82 -0.83% 1,545,890
26-10-21 US$23.01 +2.59% 1,921,006
26-10-20 US$22.43 +7.84% 1,974,847
26-10-19 US$20.80 +9.30% 2,576,189
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Viridian Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
22.37USD
Average target price
36.20USD
Spread / Average Target
+61.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Viridian Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VRDN Stock